Active Filters

  • (-) PSI Authors = Behe, Martin
Search Results 1 - 20 of 44
Select Page
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Aime, S., Al-Qahtani, M., Behe, M., Bormans, G., Carlucci, G., DaSilva, J. N., … Yang, Z. (2021). Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 6(1), 13 (19 pp.). https://doi.org/10.1186/s41181-021-00128-x
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
Gillings, N., Hjelstuen, O., Ballinger, J., Behe, M., Decristoforo, C., Elsinga, P., … Todde, S. (2021). Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 6(1), 8 (22 pp.). https://doi.org/10.1186/s41181-021-00123-2
1,5-Disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs
Grob, N. M., Schibli, R., Béhé, M., Valverde, I. E., & Mindt, T. L. (2021). 1,5-Disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs. ACS Medicinal Chemistry Letters, 12(4), 585-592. https://doi.org/10.1021/acsmedchemlett.0c00636
Improved tumor-targeting with peptidomimetic analogs of minigastrin<sup>177</sup>Lu-PP-F11N
Grob, N. M., Schibli, R., Béhé, M., & Mindt, T. L. (2021). Improved tumor-targeting with peptidomimetic analogs of minigastrin177Lu-PP-F11N. Cancers, 13(11), 2629 (12 pp.). https://doi.org/10.3390/cancers13112629
<em>In vivo</em> imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET
Taddio, M. F., Castro Jaramillo, C. A., Runge, P., Blanc, A., Keller, C., Talip, Z., … Krämer, S. D. (2021). In vivo imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET. Molecular Imaging and Biology, 23, 196-207. https://doi.org/10.1007/s11307-020-01543-3
Distance-dependent cellular uptake of oligoproline-based homobivalent ligands targeting GPCRs - an experimental and computational analysis
Dobitz, S., Wilhelm, P., Romantini, N., De Foresta, M., Walther, C., Ritler, A., … Wennemers, H. (2020). Distance-dependent cellular uptake of oligoproline-based homobivalent ligands targeting GPCRs - an experimental and computational analysis. Bioconjugate Chemistry, 31(10), 2431-2438. https://doi.org/10.1021/acs.bioconjchem.0c00484
Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes
Fonta, C. M., Arnoldini, S., Jaramillo, D., Moscaroli, A., Oxenius, A., Behe, M., & Vogel, V. (2020). Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes. Matrix Biology Plus, 8, 100046 (15 pp.). https://doi.org/10.1016/j.mbplus.2020.100046
Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions
Grob, N. M., Schmid, S., Schibli, R., Behe, M., & Mindt, T. L. (2020). Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions. Journal of Medicinal Chemistry, 63(9), 4496-4505. https://doi.org/10.1021/acs.jmedchem.9b01937
Triazolo-peptidomimetics: novel radiolabeled minigastrin analogs for improved tumor targeting
Grob, N. M., Häussinger, D., Deupi, X., Schibli, R., Behe, M., & Mindt, T. L. (2020). Triazolo-peptidomimetics: novel radiolabeled minigastrin analogs for improved tumor targeting. Journal of Medicinal Chemistry, 63(9), 4484-4495. https://doi.org/10.1021/acs.jmedchem.9b01936
Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PP-F11N
Grzmil, M., Qin, Y., Schleuniger, C., Frank, S., Imobersteg, S., Blanc, A., … Behe, M. (2020). Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N. Theranostics, 10(24), 10861-10873. https://doi.org/10.7150/thno.45440
Biodistribution of site-specific PEGylated fibroblast growth factor-2
Lühmann, T., Gutmann, M., Moscaroli, A., Raschig, M., Béhé, M., & Meinel, L. (2020). Biodistribution of site-specific PEGylated fibroblast growth factor-2. ACS Biomaterials Science & Engineering, 6(1), 425-432. https://doi.org/10.1021/acsbiomaterials.9b01248
Targeted radiotherapeutics from &#039;bench-to-bedside&#039;
Müller, C., Béhé, M., Geistlich, S., van der Meulen, N. P., & Schibli, R. (2020). Targeted radiotherapeutics from 'bench-to-bedside'. Chimia, 74(12), 939-945. https://doi.org/10.2533/CHIMIA.2020.939
Evaluation of actinium-225 labeled minigastrin analogue [&lt;sup&gt;225&lt;/sup&gt;Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy
Qin, Y., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., Béhé, M. P., & Grzmil, M. (2020). Evaluation of actinium-225 labeled minigastrin analogue [225Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy. Pharmaceutics, 12(11), 1088 (12 pp.). https://doi.org/10.3390/pharmaceutics12111088
Cholecystokinin-2 receptor agonist &lt;sup&gt;177&lt;/sup&gt;Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study
Rottenburger, C., Nicolas, G. P., McDougall, L., Kaul, F., Cachovan, M., Vija, A. H., … Wild, D. (2020). Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study. Journal of Nuclear Medicine, 61(4), 520-526. https://doi.org/10.2967/jnumed.119.233031
New insights into arrestin recruitment to GPCRs
Spillmann, M., Thurner, L., Romantini, N., Zimmermann, M., Meger, B., Behe, M., … Berger, P. (2020). New insights into arrestin recruitment to GPCRs. International Journal of Molecular Sciences, 21(14), 4949 (14 pp.). https://doi.org/10.3390/ijms21144949
L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population
Terraneo, N., Jacob, F., Peitzsch, C., Dubrovska, A., Krudewig, C., Huang, Y. L., … Grünberg, J. (2020). L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population. Cancers, 12(1), 217 (17 pp.). https://doi.org/10.3390/cancers12010217
Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins
Brandl, F., Merten, H., Zimmermann, M., Béhé, M., Zangemeister-Wittke, U., & Plückthun, A. (2019). Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. Journal of Controlled Release, 307, 379-392. https://doi.org/10.1016/j.jconrel.2019.06.030
Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients
Buitinga, M., Jansen, T., van der Kroon, I., Woliner-van der Weg, W., Boss, M., Janssen, M., … Gotthardt, M. (2019). Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients. Journal of Nuclear Medicine, 60(6), 812-816. https://doi.org/10.2967/jnumed.118.219980
High‐resolution SPECT imaging of stimuli‐responsive soft microrobots
Iacovacci, V., Blanc, A., Huang, H., Ricotti, L., Schibli, R., Menciassi, A., … Nelson, B. J. (2019). High‐resolution SPECT imaging of stimuli‐responsive soft microrobots. Small, 15(34), 1900709 (7 pp.). https://doi.org/10.1002/smll.201900709
Exendin-4 analogs in insulinoma theranostics
Jansen, T. J. P., van Lith, S. A. M., Boss, M., Brom, M., Joosten, L., Béhé, M., … Gotthardt, M. (2019). Exendin-4 analogs in insulinoma theranostics. Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), 656-672. https://doi.org/10.1002/jlcr.3750